Applied's rare disease drug suffers another phase 3 failure months after FDA rejection
Applied Therapeutics’ rare disease drug has failed another late-stage clinical trial, adding to the woes of a candidate that was rejected by the FDA five months ago.
Applied Therapeutics’ rare disease drug has failed another late-stage clinical trial, adding to the woes of a candidate that was rejected by the FDA five months ago.
